JunHe Assists SciClone Pharmaceuticals (Holdings) Limited on its Listing on m88 sport betting app Main Board of m88 sport betting app Stock Exchange of Hong Kong
2021.03.03
On March 3, 2021, SciClone Pharmaceuticals (Holdings) Limited (hereinafter referred to as "Saison Pharmaceuticals") issued approximately 116 million shares (excluding m88 sport betting app over-allotment part) worldwide and listed on m88 sport betting app main board of m88 sport betting app Stock Exchange of Hong Kong at an issue price of HK .80 per share, raising more than HK billion from investors.
SciClone Pharmaceuticals is a biopharmaceutical company with an integrated platform for product development and commercialization. m88 sport betting app company is strategically focused on some of China's largest and rapidly growing medical needs, including in m88 sport betting app areas of oncology and severe infections. With its integrated platform, SciClone Pharmaceuticals seeks to develop and commercialize a combination of quality marketed products (including its own product, Ridaxian) and drugs under development in key m88 sport betting apprapeutic areas. Its core self-owned product, Ridaxian (a new original drug based on m88 sport betting app thymus method), played an important role in preventing and treating SARS in 2003 and 2020, and is widely used in m88 sport betting app combined treatment of hepatitis B, sepsis and tumor.
JunHe acted as m88 sport betting app co-sponsors and underwriter’s PRC legal counsel of this Project and provided high quality, rigorous and efficient legal services. JunHe’s team overcame m88 sport betting app many adverse effects of m88 sport betting app epidemic and assisted m88 sport betting app co-sponsor in carrying out due diligence. m88 sport betting app team reviewed and amended m88 sport betting app prospectus, m88 sport betting app application and m88 sport betting app offering documents related to this listing. m88 sport betting appy issued PRC legal opinions and assisted in replying to feedback questions from m88 sport betting app Hong Kong Stock Exchange regarding PRC law. SciClone Pharmaceuticals was investigated by m88 sport betting app SEC during its US listing and reached a settlement agreement with m88 sport betting app SEC. m88 sport betting app Hong Kong Stock Exchange was concerned about m88 sport betting app potential compliance issues in its history.
JunHe assisted m88 sport betting app Sponsor to carry out a deep examination of m88 sport betting app situation and assisted m88 sport betting app Sponsor to successfully reply to m88 sport betting app feedback questions from m88 sport betting app Stock Exchange of Hong Kong, ultimately helping Saisheng Pharmaceutical to successfully obtain m88 sport betting app approval and consent of m88 sport betting app listing application from m88 sport betting app Stock Exchange of Hong Kong. JunHe 's solid work attitude and professional service won unanimous appreciation and trust from m88 sport betting appir clients and om88 sport betting appr intermediaries.
